Connect with us

Covid

All you need to know about Mucormycosis: Dos and Don’ts

Published

on

What is Mucormycosis?

Mucormycosis is a fungal infection that mainly affects people who are on medication for other health related problems that reduces their ability to fight environmental pathogens.

Lungs or Sinuses of such individuals get affected after fungal spores are inhale from the air. And this leads to serious disease. Below are the symptoms.

  1. Pain and redness around eyes or nose
  2. Fever
  3. Headache
  4. Coughing
  5. Shortness of breath
  6. Bloody vomits
  7. Altered mental status

What predisposes?

Uncontrolled diabetes mellitus

Immunosuppression by steroids

Prolonged ICU stay

Co-morbidities – post transplant/malignancy

Voriconazole therapy

How to prevent?

Use masks if you are visiting dusty construction sites

Wear shoes, long trousers, long sleeve shirts and gloves while handling soil (gardening), moss or manure

Maintain personal hygiene including thorough scrub bath

When to Suspect?

Sinusitis – nasal blockade or congestion, nasal discharge (blackish/bloody), local pain on the cheek bone

One sided facial pain, numbness or swelling

Blackish discoloration over bridge of nose/palate

Toothache, loosening of teeth, jaw involvement

Blurred or double vision with pain; fever, skin lesion; thrombosis & necrosis (eschar)

Chest pain, pleural effusion, haemoptysis, worsening of respiratory symptoms

Dos:

Control hyperglycemia

Monitor blood glucose level post COVID-19 discharge and also in diabetics

Use steroid judiciously – correct timing, correct dose and duration

Use clean, sterile water for humidifiers during oxygen therapy

Use antibiotics/antifungals judiciously

Don’ts

Do not miss warning signs and symptoms

Do not consider all the cases with blocked nose as cases of bacterial sinusitis, particularly in the context of immunosuppression and/or COVID-19 patients on immunomodulators

Do not hesitate to seek aggressive investigations, as appropriate (KOH staining & microscopy, culture, MALDITOF), for detecting fungal etiology

Do not lose crucial time to initiate treatment for mucormycosis

How to manage?

Control diabetes and diabetic ketoacidosis

Reduce steroids (if patient is still on) with aim to discontinue rapidly

Discontinue immunomodulating drugs

No antifungal prophylaxis needed

Extensive Surgical Debridement – to remove all necrotic materials

Medical treatment

  1. Install peripherally inserted central catheter (PICC line)
  2. Maintain adequate systemic hydration
  3. Infuse Normal saline IV before Amphotericin B infusion
  4. Antifungal Therapy, for at least 4-6 weeks (see the guidelines below )

Monitor patients clinically and with radio-imaging for response and to detect disease progressions.

For further information and consultation:

For any queries , kindly email to drtidybiz@gmail.com

Covid

Covid-19 in India: 18,987 new cases in last 24 hours, 20% higher than day before

Published

on

By

Covid-19 in India: 18,987 new cases in last 24 hours, 20% higher than day before

The Union Ministry of Health and Family Welfare (MoHFW) said on Wednesday said that India registered 18,987 new Covid-19 cases in the last 24 hours, which was 20 per cent higher than what the country had witnessed a day before.

Also, total of 246 deaths were reported during the same time, increasing the total reported death count to 4,51,435.

With this, the total Covid caseload in India has increased to 3,40,20,730.

The top five states which have registered maximum cases are Kerala with 11,079 cases, followed by Maharashtra with 2,219 cases, Tamil Nadu with 1,280 cases, Mizoram with 1,028 cases and West Bengal with 771 cases.

Continue Reading

Covid

Covaxin gets emergency use approval for kids aged 2-18 years

Published

on

By

Covaxin gets emergency use approval for kids aged 2-18 years

The Subject Expert Committee (SEC) on Covid-19 has granted emergency use approval to Bharat Biotech’s Covaxin for children in the 2-18 years age group.

In September, Hyderabad-based Bharat Biotech had completed Phase-2 and Phase-3 trials of Covaxin on children below 18 years of age and also submitted the trial data to the Drugs and Comptroller General of India (DCGI).

“After detailed deliberation, the committee recommended for grant of market authorization of the vaccine for the age group of 2 to 18 years for restricted use in emergency situation,” the subject expert panel said in a statement.

 

Continue Reading

Covid

Govt has no data of Covid-19 vaccines given daily by private hospitals

Published

on

By

Govt has no data of Covid-19 vaccines given daily by private hospitals

The Union health ministry has said that it does not hold data of daily Covid-19 vaccines doses administered by private hospitals and health service providers.

In a response to RTI petition and appeal filed by activist Commodore (Retd) Lokesh Batra, the government has said the same

In its first reply, the government mentioned, “Private hospitals/institutions etc procure vaccines directly from the vaccine manufacturers. Data asked pertains between manufacturers and private hospitals/institutions etc. Separate vaccination data is not available, however, the vaccination data ll date can be checked on the below link hps://dashboard.cowin.gov.in/ (sic).”

“This information is not maintained and is not available since procurement of vaccines by private hospitals private healthcare service providers and private entities are done directly from the manufacturers,” the Union health ministry said.

Continue Reading

Trending